Get started

Covid19stock

Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores. The company generates a majority of its revenue from its retail segment. The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19. www.benzinga.com twitter.com
I
by AlenCiken
CBDT -- Symmetrical Triangle breakout on REXALL partnership newsSymmetrical Triangle breakout. Bullish MACD cross. Likely gap up tomorrow after major news today: Empower Partners with Rexall(R) To Launch Integrated Healthcare Centres Partnership Accelerates Empower's Strategy To Execute National Healthcare Centre Expansion By Bringing Accessible and Progressive Primary Care and Para-Medical Care to Millions of Canadians VANCOUVER, BC / ACCESSWIRE / February 9, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada. "In our first press release of 2021 announcing the closing of our Canadian Clinics acquisition, I stated Empower had a winning business model with immediate expansion plans throughout Greater Toronto, followed by Ontario and then nationwide with at least 30 clinics in rapid succession. Empower is proud to begin delivering on that promise." said Steven McAuley, Chairman & CEO. "To say this is the Company's biggest announcement in its history would not be an over statement. This partnership with Rexall accelerates our nationwide healthcare expansion strategy, I look forward to bringing Six Sigma philosophies and continuous process improvements to our operations to ensure customers and our patients have access to our primary care and para-medical services for years to come. Today marks a major win for Canadian healthcare and the shareholders of Empower Clinics." PARTNERSHIP IDENTIFIES INITIAL LOCATIONS IN ONTARIO Rexall and Empower have identified numerous initial locations throughout Ontario, spanning from Ottawa to London and around the GTA. The size of the locations can range from 1,500 to 4,000 square feet. As each new location is agreed upon, key terms are outlined in a letter of intent and in the lease or sub-lease agreements with the first anticipated agreements February 2021. HEALTH CARE SERVICES TO BE DELIVERED Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location. Primary care services include: Family physicians Walk-in physicians Tele-medicine and virtual care Paramedical services include: Chiropractic Physiotherapy Registered Massage Therapy Chiropody Acupuncturists Osteopaths Nutritionists ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include: Dermatology Cardiology Empower is currently in advanced discussions with potential partners in each of these specialty areas and believes they hold the potential to add significant value to the operations of each healthcare centre. This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management agoracom.com
C
by wealth_bakery
3
Long #ENLV above 18.50, COVID news#ENLV is in the news last week with regards to Covid-19 treatment. I would be looking at the 18.46 area for a retest, and possible entry if we find support. 100% measured move would take the breakout to 23.81 and ultimately that would be my first target. Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a longer term position and consider the 10.72-12.32 for a reentry. Based on trend projection confluence and fib levels, id be looking to sell some shares at the 28.00 level If we happen to see price action above these levels, i would consider targeting 37$ down the road. The top of this trading range would be close to $45, Currently trading at 15.49
NASDAQ:ENLVLong
by TradingNomadic
OCGN - how to play the COVAXIN news !OCGN: What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken – double-check me on it – except AstraZeneca all of them need cooling. The vaccine of Ocugen is in cooperation with Bharat Biotech. the vaccine is supposed to be stronger against different strains of covid that are emerging …. The reason for all the noise is in the fine print -they closed a damn good deal on the sales in the U.S – they will receive 45% of profits with no upfront payment (someone was drunk when he agreed to that deal LOL)… so price target given by Roth Capital is 8$ -don’t agree – I think in the next year if all goes well this stock is above 15$ if we factor in the “meme” market going on could be much more and much faster but let's stay conservative. Ok lets talk shop – technical: POC (point of control) is not good – 3,18 but I am certain it will rise in the upcoming week – remember POC is like a “magnet” it will attract the price to it for obvious reason. Volume: average volume is 63M, last 2 days trading above 100M. 50% line of retracement is 3.95 (round it up to the 4$ area – its always areas not specific numbers ) which means we will need to see the golden number getting touched sooner or later (again consider “meme” market conditions are extremely abnormal) 4.5$ -6$ needs to be retested – there needs to be a retracement to that area with some sideways trend before we can say let’s see 8$ - in normal market conditions…. Notice on the chart the yellow square showing ling upper wicks meaning buying power got very weak – matches the volume orders on the left (the colors are somewhat faded meaning it needs accumulation), reversal signal. The red box in the lower part of the chart is the forbidden zone – it is the other side of the POC and the stock flew through that price too quick so if we see a pullback to the POC line we may see a sell-off to that area- don’t believe this will happen so soon as sentiment is very high Bottom line – I think we need to see some pull back the upcoming days before the stock goes higher to the next level of 7$-usually happens after a 2-3 days rally and once that is done we can target 7$+. Please keep in mind we are trading on a very speculative market and everything is highly inflated along with 1.9T $ coming and meme trend this is a very risky market and using my analysis on it can mean shit because it is NOT BEHAVING like it should at all !! FDGT will wait for a pullback before entering as the trend doesn’t look healthy This is not a recommendation of any sort Trader safe and be safe – we are the traders union and we trade by our own rules!
NASDAQ:OCGNLong
by FDGT_academy
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US. COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients. COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape. today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market . B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits. In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program. H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market. Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements. Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday. Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
NASDAQ:OCGN
by AlenCiken
4
Lexaria Provides Guidance on Upcoming R&DLexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The shares of common stock and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 274,285 shares of common stock and/or warrants to purchase up to 274,285 shares of common stock. finance.yahoo.com Lexaria Provides Guidance on Upcoming R&D Lexaria recently closed an oversubscribed financing of US$11 million that has greatly enhanced the Company's ability to conduct applied R&D designed to evidence effectiveness of its patented DehydraTECHTM drug delivery technology across multiple classes of bioactive substances or drugs. In the weeks to come, Lexaria expects to announce many new studies designed to provide initial evidence expected to support further study and commercial exploitation. All studies referenced within this press release are fully funded from existing Company resources. finance.yahoo.com
NASDAQ:LEXX
by AlenCiken
TYME Granted U.S. Patent Claims Treat COVID-19 InfectionsTYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19. Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19. TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication. finance.yahoo.com
T
by AlenCiken
1
HFG continue its upward long-term trendThe long-term trend chart of profitable HELLOFRESH is presented. Its rising is supported by its strong fundamentals. ___ Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile. Disclaimer The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only. It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances, it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
XETR:HFGLong
by Gnothisafton
Potential Development of an Oral COVID-19l VaccineAeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19. - Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement. to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine. Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19. A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial. finance.yahoo.com Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
A
by AlenCiken
Corona(Covid 19 vaccine) stock that can explode in 2021A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed? over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and BioNTech. In fact, over 30% of Vaxart stock has been sold short. Vaxart claims to have created an experimental coronavirus vaccine in the form of an oral tablet. One could potentially self-administer the vaccine pill, which is stable at room temperature. This would allow patients to order the vaccine online and have it delivered for at-home use. At the moment, Vaxart's experimental coronavirus vaccine is only in phase 1 clinical trials, with a new data readout expected by next week. Unfortunately, it's impossible to conclude how the experimental vaccine will work on humans from animal models. Hence, the candidate's phase 1 data release will likely be a make-or-break moment for Vaxart. Vaxart is under investigation by both the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for insider trading and inaccurate statements regarding its role in Operation Warp Speed (OWS). Even though Vaxart has more than $133 million in cash and equivalents with no debt whatsoever, that's not nearly enough to move forward. Right now, it could cost billions of dollars to run a potential coronavirus vaccine through clinical trials involving tens of thousands of participants. The company will likely sell more stock to pay for its research and development (R&D) expenses or apply for grant funding -- just to stay afloat. Vaxart is far riskier than the other coronavirus vaccine drugmakers out there. Its corporate conduct is under federal investigation, and its vaccine candidate is in far too early a stage to draw any definitive conclusions about. With a market cap just south of $1 billion, it will undoubtedly become a very undervalued stock if it can bring a coronavirus vaccine to market. Moderna, which has done so, projects $11.7 billion in revenue from its mRNA-1273 vaccine alone. However, the probability of Vaxart achieving anything remotely similar is up for debate. Short-sellers and passionate bulls will be arguing over the stock for the next year. If you believe in Vaxart's science and have the stomach for a roller-coaster ride, then go for it.
NASDAQ:VXRT
by AlenCiken
COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 TrialNovavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). Novavax also announced successful results of its Phase 2b study conducted in South Africa. Significant progress on PREVENT-19 Clinical Trial in US and Mexico finance.yahoo.com
NASDAQ:NVAX
by AlenCiken
MRNA (TESLA of biotechnology) towards new highsAfter making a major price correction throughout December, MRNA started in 2021 a new upward movement that is ongoing and leading it to new highs. Note that 1) the correction was made with a very large volume, which means that the shares left the portfolios of the many and passed into those of the few 2) the RSI has not yet entered the overbought area and 3) it is possible (but perhaps not necessary) to retreat prices close to the previous peak to create a cup-forming handle. MRNA's upward move is supported by both the expected big sales revenue of its vaccine for Covid-19, and a promising large pipeline of new drugs and vaccines comprising 27 products under development. MRNA as well as INO is likely the TESLA of Biotechnology. Following is presented the short-term trend chart of the stock. Disclaimer The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only. It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances, it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
NASDAQ:MRNALong
by Gnothisafton
1
EDSA to Study Investigational Drug as Potential Rescue TheraphyEdesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy EDSA has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The sub-study will evaluate the drug as a potential rescue therapy for critically severe COVID-19 cases. This sub-study will allow us to potentially expand the use of EB05 to critically ill patients suffering from profound, medically refractory COVID-19 respiratory failure," Dr. Nijhawan said. finance.yahoo.com
NASDAQ:EDSA
by AlenCiken
HelloFresh: profitable growth stock with a reasonable valuationHelloFresh is a multinational German company that delivers home, packaged in a box, the fresh ingredients of its recipes selected online by the customer to cook them in their kitchen in half an hour. HelloFresh operates in Germany, USA, Australia, Austria, Belgium, Canada, the Netherlands, Switzerland, and the United Kingdom. Its anyway strong growth accelerated in 2020 due to CORONAVIRUS. Regarding its profitability, we do not just hope that the company will likely become profitable sometime, it is already profitable, and its valuation is very reasonable given its growth. Below are presented the mid- and short-term trend charts of HelloFresh. Disclaimer The writer of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only. It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances, it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
XETR:HFGLong
by Gnothisafton
Adamis Surges After Submitting Covid Drug to FDAAdamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls (CMC) and Clinical aspects to be included in the IND. The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol. Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. finance.yahoo.com
A
by AlenCiken
1